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Abstract
Clozapine (CLZ) is the superior antipsychotic drug for treatment of schizophrenia, but exhibits an extensive
interpatient pharmacokinetic variability. Here, we conducted a genome-wide association study (GWAS) of CLZ serum
concentration adjusting for known smoking habits, which is a major nongenetic factor reducing CLZ levels. The study
included 484 patients with 10,283 steady-state serum concentrations of CLZ and N-desmethylclozapine, prescribed
dosing, co-medications and known smoking habits (n= 422; 9284 serum samples) from a therapeutic drug
monitoring (TDM) service. The GWAS analyses were performed with and without smoking habits as covariate, where
possible hits were assessed in relation to the target CLZ concentration range applied in the TDM service
(300–2500 nmol/L). The smoking-independent analysis of N-desmethylclozapine serum concentration and the CLZ-to-
N-desmethylclozapine ratio replicated the previously identified locus on chromosome 4. After adjusting for smoking
habits in patients confirmed as ‘smokers’ (61%) or ‘nonsmokers’ (39%), a novel variant (rs28379954; minor T>C allele
frequency 4.1%; 7.6% CT carriers in the population) within the gene encoding the nuclear factor 1 B-type (NFIB) was
significantly associated with reduced CLZ serum concentration (p= 1.68 × 10−8, beta=−0.376; explained variance
7.63%). There was no significant association between rs28379954 and N-desmethylclozapine concentration in the
GWAS analysis (p= 5.63 × 10−5). The fraction of CLZ TDM samples below 300 nmol/L was significantly higher in
carriers vs. noncarriers of the rs28379954 minor C allele [12.0% (95% CI: 9.4–14.7) vs. 6.2% (95% CI: 5.7–6.8), p < 0.001].
We identified a novel variant in the NFIB gene associated with reduced CLZ levels and increased risk of subtherapeutic
serum concentrations. This warrants testing of clinical relevance of screening for this gene variant, and also
experimental studies to investigate the biological mechanisms of NFIB involvement in CLZ pharmacokinetics.
Introduction
Clozapine (CLZ) is the most efficient antipsychotic drug
in treatment of schizophrenia1. However, CLZ is only
indicated in treatment-resistant schizophrenia (TRS) due
to risk of neutropenia or agranulocytosis2,3, which is
reported to occur in about 3% and 0.5–1% of the patients,
respectively4. Therefore, close monitoring of neutrophil
granulocyte counts is mandatory during use of CLZ5. The
suppression of granulocyte levels, as well as risk of other
adverse effects such as seizures, cardiometabolics (weight
gain and type 2 diabetes), sedation, and hypersalivation,
have been associated with CLZ and/or metabolite levels6,7.
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CLZ is subjected to complex metabolism involving
biotransformation via multiple pathways8,9. Several cyto-
chrome P450 (CYP) enzymes, including CYP1A2,
CYP3A4, CYP2D6, and CYP2C19, are in vitro shown to
be involved in the oxidative metabolism of CLZ to the
major metabolites N-desmethylclozapine and clozapine-
N-oxide9. In addition, CLZ undergoes metabolism to
reactive nitrenium ion metabolites, which are believed to
be important for the toxicity of CLZ treatment10,11. Less is
known about the enzyme(s) mediating the formation of
nitrenium ion metabolites of CLZ, but the myeloperox-
idase system in granulocytes seem to play a role9,12.
Previous studies have shown that interindividual varia-
bility in CLZ concentration is significantly associated with
age, sex, and smoking habits13,14, where the latter is
quantitatively most important. However, these factors only
explain parts of the variability, which has motivated the
search for pharmacogenetic determinants of CLZ phar-
macokinetics. Most studies so far have been unsuccessful
in identifying genetic polymorphisms associated with
individual variability in CLZ pharmacokinetics15, but
recently a genome-wide association study (GWAS) in a
British patient population (n= 2989) identified a single
locus (15:74817689–75404506) between the CYP1A1
and CYP1A2 genes associated with a reduction in CLZ
serum levels16. Further, a locus on chromosome 4
(4:69542100–70387482), containing the UGT2B10 gene,
was associated with both N-desmethylclozapine serum
concentration and the CLZ-to-N-desmethylclozapine
metabolic ratio. For the N-desmethylclozapine serum
concentration and CLZ-to-N-desmethylclozapine meta-
bolic ratio two additional loci were identified16, i.e., at
chr2:234611523–234676118 and 10:96098093–96974830,
respectively. In contrast to polygenic complex traits, such
as schizophrenia17, these results support the hypothesis
that the genetic architecture of CLZ metabolism is less
polygenic and may constitute a smaller number of variants
with larger effect sizes16,18. This is typical for the phar-
macogenetics of drug-metabolizing enzymes, where a
limited number of variant allele diplotypes have large
effect sizes and separate the population into distinct
metabolizer phenotypes19,20. In addition, CLZ related
adverse effects are associated with few genetic variants
with large effect sizes21,22.
Tobacco smoke reduces the serum concentration of
CLZ by ~30–50% due to polycyclic aromatic hydro-
carbons inducing gene transcription of drug-
metabolizing enzymes, e.g., CYP1A enzymes23–25.
Thus, information on smoking habits is crucial when
studying factors that may influence the CLZ serum
concentrations. The previous British GWAS did not
account for the individual patient’s smoking habits16, but
used a proxy measure (polygenic risk scores for smok-
ing), which may imply that significant variants were not
captured in the analysis. The aim of the present study
was to perform a GWAS on serum concentrations of
CLZ and its main metabolite N-desmethylclozapine in a




Patients with serum concentration measurements of
CLZ and the metabolite N-desmethylclozapine, and bio-
banked blood samples for genotyping, were included from
the therapeutic drug monitoring (TDM) service at the
Center for Psychopharmacology, Diakonhjemmet Hospi-
tal, Oslo, Norway, from March 2005 to May 2019. Inclu-
sion criteria were: (i) blood sampling for serum
concentration analysis of CLZ at steady-state conditions
and 10–30 h after the last drug intake, and (ii) prescribed
daily dose of CLZ. For the GWAS analysis adjusting for
smoking only, a further inclusion criterion was (iii) infor-
mation about confirmed smoking habits written by the
physician on the TDM requisition form (cigarette smoking
‘yes’ or ‘no’). The time intervals between last dose intake
and blood sampling for serum concentration analysis, and
the psychotropic co-medication profiles, were obtained
from the requisition forms. Exclusion criteria were (i)
concurrent use of interacting drugs, i.e., the CYP1A2/
2C19/3A4 inhibitor fluvoxamine, or the CYP3A4/2C19
inducers phenobarbital, phenytoin, and carbamazepine,
and (ii) concentration of CLZ or N-desmethylclozapine
below the lower limit of quantification (LLOQ; i.e.,
20 nmol/L). All serum concentration measurements from
each of the patients fulfilling the criteria were included in
the statistical analyses, as described below.
The study was approved by the Regional Committee for
Medical and Health Research Ethics and the Hospital
Investigational Review Board. As the study was solely
based on historical data, the project did not have the
potential to cause any harm or burden, informed patient
consent was not required.
Clinical characteristics
The study population consisted of patients with TRS as
determined by TDM of CLZ per se, since use of this drug is
solely indicated for TRS3. In Norway, TDM analyses are
reimbursed by the governmental health service, and it is used
as a tool for clinical follow-up in psychiatry. The analyses are
typically requested as a routine control to monitor e.g.,
adherence and drug–drug interactions, or to assess adverse
effects or lack of effect, in relation to a therapeutic con-
centration reference range. All results from the analyses are
interpreted by the TDM laboratory against the therapeutic
reference range as basis for the reports sent to the physicians.
The therapeutic reference ranges used in our TDM service
are based on international standards as defined by the AGNP
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working group26. However, they are adjusted according to
the concentrations measured at our laboratory in a Norwe-
gian patient population during therapeutic dosing. In the
case of CLZ, the applied therapeutic reference range at our
laboratory is 300–2500 nmol/L, while the AGNP reference
range is 1071–1835 nmol/L. The AGNP definition of
1071 nmol/L (=350 ng/ml) as the lower therapeutic con-
centration boundary is based on several studies correlating
clinical response and serum concentration of CLZ, e.g., the
study by Perry et al. showing that only 22% of the patients
with concentration <350 ng/mL were responders (i.e., ≥20%
reduction in symptom score), while 64% of the patients above
the limit were responders27. This was supported by a follow-
up study where the majority of nonresponders achieved
clinical effects when the serum CLZ levels were raised above
350 ng/mL28. However, in the present study, we use a more
conservative lower serum concentration boundary, i.e.,
300 nmol/L, since it is applied in our clinical TDM service
based on Norwegian data. Use of 300 nmol/L as the lower
boundary also increases the likelihood of poor clinical effi-
cacy of CLZ when serum concentrations are below this
threshold. In addition, a CLZ concentration of 300 nmol/L
corresponds with a brain dopamine-2 (D2) receptor occu-
pancy of about 20–40%, which is regarded as critical for
clinical effect29.
The TDM service at the Diakonhjemmet Hospital in
Oslo analyses serum samples from psychiatric patients
mainly located in the South-Eastern Norway Regional
Health Authority, and ~25% of the submitted samples are
from hospitalized patients.
Genotyping and imputation
DNA was extracted from whole blood and genotyped
with the Human Omni Express-24 v.1.1 array (Illumina Inc.,
San Diego, CA, USA), at deCODE Genetics (Reykjavik,
Iceland), in accordance with the standard Illumina protocol.
Standard pre-imputation quality control was performed
using PLINK v1.930,31. Finally, chromosome-wide haplo-
types were phased with Eagle232,33 and missing variants
were imputed with Minimac334 using the first release of the
haplotype reference consortium reference set. After impu-
tation, we removed variants if their minor allele frequency
was <1% or if they showed departure from
Hardy–Weinberg equilibrium (P-value <1 × 10−6). Fur-
thermore, we removed related individuals (pairwise
Identity-By-Descent π̂ > 0.2 according to PLINK v1.930,31)
and those individuals with high rates of genotyping miss-
ingness (>5%). The final dataset included 484 unrelated
individuals and ~6.2 million variants for analysis.
GWAS of serum concentrations with and without adjusting
for smoking habits
We applied a regression modeling framework to com-
bine serum concentration measurements of each patient
from multiple time points into a single phenotype, as
described previously16. The R package fitdistrplus v1.0-14
was used to determine the best-fitting distribution for
each phenotype outcome variable (dose-adjusted serum
concentrations of CLZ and N-desmethylclozapine, and
the CLZ-to-N-desmethylclozapine metabolic ratio).
Thereafter, the R package gamlss v5.1-2 was used to
specify a random-effects model for each phenotype out-
come variable. The fixed effect covariates in the model
included known predictors of CLZ serum concentration
(CLZ dose, age at sampling and time between sampling
and last dose intake). In addition, a random effect was
added to model the distribution of the outcome in each
individual, controlling for these covariates. The inclusion
of this random effect for each individual permits unba-
lanced data patterns (differing number of serum mea-
surements) in the model35. For each model, the
coefficients of this random effect for each individual were
extracted. These coefficients correspond to the variation
within the serum concentrations for each individual
independent of the included covariates, and were used as
the outcome phenotypes for the GWAS analyses.
We conducted a GWAS for each outcome phenotype
(variation in serum concentrations of CLZ and N-des-
methylclozapine, and the CLZ-to-N-desmethylclozapine
metabolic ratio) using linear regression analyses imple-
mented in PLINK v1.930,31, controlling for participant age,
sex, the first 20 genetic principal components, and gen-
otyping batch. We also performed a GWAS for each
outcome phenotype in the sample with known smoking
habits (n= 422) by adding this variable as a covariate in
the regression models.
Details describing the methods used for gene loci defi-
nitions and annotations, estimating the single-nucleotide
polymorphism (SNP) proportion of variance explained,
and follow-up GWAS meta-analyses with the British
sample including testing the effect of smoking PRS as
proxy for smoking and body mass index, are included in
the Supplementary file (Supplementary Methods; Sup-
plementary Figs. 1–4 and Supplementary Tables 1 and 2).
Also included is a methodological description of the tar-
geted Taqman genotyping used for verification of SNPs
significantly associated with CLZ concentration in
the GWAS.
Follow-up analyses of SNPs identified in the GWAS
For SNPs significantly associated with CLZ concentra-
tion in the GWAS, the various phenotypes were com-
pared in carriers vs. noncarriers of the identified variant(s)
using linear mixed model analysis. These analyses were
performed for both smokers and nonsmokers adjusting
for sex, age, and sampling time as covariates. The Pearson
Chi-square test was used to evaluate the potential differ-
ences in proportion of patients with TDM measurements
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of CLZ either below or above the defined target con-
centration range (300–2500 nmol/L; c.f. information
provided in the beginning of the “Methods” section).
Statistical tools
The statistical analyses were performed using R statis-
tics and PLINK v1.930,31 for the GWAS and SPSS® (ver-
sion 25.0) for the assessments of the significant GWAS
hits, as described above.
Results
Sample characteristics
The study population comprised 484 CLZ-treated
patients with a total of 10,283 CLZ and N-desmethylclo-
zapine serum concentrations measurements (Table 1),
with median age of 37 years (IQR: 29–47) and 38.4%
females (n= 186). The median prescribed daily dose of
CLZ was 400mg (IQR: 250–500mg), whereas the median
serum concentration of CLZ and N-desmethylclozapine
were 1167 and 770 nmol/L, respectively. Among the
patients with known smoking habits (n= 422; 9284 serum
samples), 258 were confirmed smokers (61.1%) and 164
were confirmed nonsmokers (38.9%). The median dose-
adjusted CLZ serum concentrations (C/D ratio) were
2.46 nmol/L/mg (IQR: 1.67–3.64) and 4.63 nmol/L/mg
(IQR: 2.91–6.49) in smokers and nonsmokers, respec-
tively, whereas the median CLZ-to-N-desmethylclozapine
ratios were 1.43 (IQR: 1.17–1.71) in smokers and 1.69
(IQR: 1.40–2.06) in nonsmokers.
GWAS of serum concentrations adjusting for smoking
habits
The GWAS of CLZ serum concentration, adjusting for
smoking habits (n= 422), identified a single novel genome-
wide significant locus at chromosome 9 (Fig. 1a, Table 2 and
Supplementary Fig. 5a), represented by lead SNP
(rs28379954, p= 1.677 × 10−8, 9:14163907). Data from the
1000 Genomes phase 3-genome browser shows that this
SNP lies within an LD-sparse region (Supplementary Fig. 6).
However, four other SNPs, in LD with the lead SNP (r2 >
0.2) and within 250 kb, showed nominal significance (p <
1.000 × 10−4): rs10481501 C>T (9:14172871, p= 4.506 ×
10−7, LD r2= 0.554), rs10961406 A>G (9:14182043, p=
3.856 × 10−5, LD r2= 0.451), rs10120632 G>C (9:14226937,
p= 3.892 × 10−5, LD r2= 0.329) and rs12156582 C>T
(9:14163383, p= 4.546 × 10−6, LD r2= 0.411; Supplemen-
tary Fig. 7).
The rs28379954 variant is located within an intron
of the nuclear factor 1 B-type (NFIB) gene and the
minor C allele (C allele frequency= 0.041; explained
variance 7.63%) was associated with reduced CLZ
serum concentration (beta =−0.3755; Table 2 and
Fig. 1a). The NFIB genotypes from GWAS and tar-
geted Taqman analyses of rs28379954 T>C showed
97% consistency, supporting the significant associa-
tion with CLZ serum concentration. Functional ana-
lyses do not suggest this SNP, or the four others in LD
(r2 > 0.2), to be deleterious (CADD scores: <12.37) or
likely to have regulatory functionality (RegulomeDB
scores = 5–7). Furthermore, none of these SNPs were
associated with any other phenotype in the GWAS
catalog and none were identified as potential eQTLs in
the GTEx portal.
GWAS analyses of N-desmethylclozapine serum con-
centration and the CLZ-to-N-desmethylclozapine ratio as
phenotypes, adjusting for smoking habits, revealed the
same significant loci as those identified in the GWAS
analyses by Pardiñas et al.16. (Fig. 1b, c, Table 2, and
Supplementary Fig. 5b, c). We did not replicate the
additional locus associated with N-desmethylclozapine
serum concentration in the study by Pardiñas et al.16
(2:234611523–234676118). Of the 242 SNPs within this
region, the most significant association to N-desmethyl-
clozapine concentration was identified for rs17862876
(p= 0.059, beta=−0.227). Furthermore, we did not
replicate the additional locus associated with the CLZ-to-
N-desmethylclozapine ratio (10:96098093–96974830). Of
the 2098 SNPs within this region, the most significant
association to the CLZ-to-N-desmethylclozapine ratio
was identified for rs66634733 (p= 1.065 × 10−4, beta=
0.80). Functional annotation of the lead SNPs from these
GWAS did not predict any deleterious effects on protein
structure/function and did not suggest any regulatory
functionality (Table 2).
Among the patients with smoking habits data (n= 422),
32 patients (7.6%) were in the GWAS identified as
rs28379954 minor C allele carriers. In Fig. 2a, the linear
regressions of absolute, unadjusted CLZ serum con-
centration vs. prescribed daily dose are shown according
to rs28379954 genotype. As compared with the
rs28379954 TT genotype carriers (smokers: 2.31 (95% CI:
2.19–2.44); nonsmokers: 3.39 (95% CI: 3.15–3.64)), the C
allele carriers (smokers: 0.81 (95% CI: 0.56–1.06);
Table 1 Population characteristics.
Variables Value
No. of patients, n (measurements) 484 (10,283)
Male/female, n 298/186
Age, years; median (IQR) 37 (29, 47)
No. of measurements per patient; median (IQR) 13 (5, 28)




Clozapine dose, mg (IQR) 400 (250, 500)
Withdrawal time (time between dose and sampling),
h, median (IQR)
13.1 (12.2, 14.5)
Smoking habits, n (%) 422 (87.2)
Smoker/nonsmoker (% females) 258 (31.4)/164 (48.2)
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nonsmokers: 0.77 (95% CI: 0.37–1.16)) had a significantly
lower linear slope (Fig. 2a). This was reflected by a sig-
nificantly higher proportion of CLZ serum concentrations
below the therapeutic range (<300 nmol/L) in C vs. TT
allele-carrying smokers (16.0% vs. 7.2%, p < 0.001) and
nonsmokers (8.0% vs. 4.9%, p= 0.017), despite similar
daily dosing (p > 0.05). Regarding the pharmacokinetic
effect of rs28379954, C allele carriers had an ~42% lower
CLZ dose-adjusted serum concentration than TT geno-
type carriers in smokers (p= 0.004), whereas the C allele-
carrying nonsmokers had 33% lower CLZ dose-adjusted
serum concentration ratio than the TT genotype carrying
nonsmokers (p= 0.031; Fig. 2b), after adjusting for age,
sex, and sampling time as covariates. The dose-adjusted
serum concentration of N-desmethylclozapine and CLZ-
to-N-desmethylclozapine ratio were not associated with
the rs28379954 C>T polymorphism in the GWAS ana-
lyses (Table 2). Due to reduced substrate (CLZ) avail-
ability, the rs28379954 C allele carriers still had 30% and
31% lower dose-adjusted serum concentration of N-des-
methylclozapine compared with the smoking (p= 0.029)
and nonsmoking (p= 0.016) TT genotype carriers,
respectively (Fig. 2c). In smoking rs28379954 TT allele
carriers, the CLZ-to-N-desmethylclozapine ratio was 19%
(p= 0.014) higher than in smoking C allele carriers
(Fig. 2d), while no significant change in CLZ-to-
desmethylclozapine ratio was observed among C allele-
carrying nonsmokers (p= 0.265; Fig. 2d).
GWAS of serum concentrations without adjusting for
smoking habits
Without adjusting for smoking habits, we identified no
genome-wide significant loci in our GWAS of CLZ serum
concentration (Fig. 1a and Supplementary Fig. 8a). Further
investigation of the previously implicated CYP1A locus on
chromosome 15 (15:74817689–75404506)16 showed that
the lead SNP rs2472297 had a call rate of 64.2% and was
therefore excluded from our GWAS analyses. However,
773 SNPs were present within this locus, and the most
significant association was observed for rs11635266 T>C
(15:75386649) at p= 0.002 (beta= 0.080).
Fig. 1 Manhattan plots showing clozapine concentration,
N-desmethylclozapine concentration, and metabolic ratio
associations. Circular Manhattan plots for (A) clozapine serum
concentration, (B) N-desmethylclozapine serum concentration, and (C)
Clozapine-N-desmethylclozapine metabolic ratio. The inner plot
shows the results from the initial GWAS without controlling for
smoking habits. The outer plot shows the results of the GWAS after
controlling for smoking habits. The −log10 transformed p-values for
each SNP are indicated on the y-axes and chromosomal positions
along the exterior of the plot. The dashed red line represents the
threshold for significant associations (p<5×10−8). SNPs surpassing this
threshold are indicated in red.
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Our analysis of N-desmethylclozapine serum concentra-
tion and the CLZ-to-N-desmethylclozapine ratio replicated
the significant locus on chromosome 4 (Fig. 1b, c, Table 2
and Supplementary Fig. 8b, c) reported by Pardiñas et al.16,
regardless of adjusting for smoking habits (p < 1.62 × 10−8).
On the other hand, we did not replicate the additional loci
previously associated with N-desmethylclozapine serum
concentration (2:234611523–234676118) or with the CLZ-
to-N-desmethylclozapine ratio (10:96098093–96974830),
respectively.
Meta-analyses of our smoking-independent GWAS and
the previously published British GWAS16 did not identify
any novel significant loci, while all previously identified
loci were retained (Supplementary Figs. 1 and 2,
Supplementary Table 1).
Discussion
The present study replicated the previously identified
locus on chromosome 4 for both N-desmethylclozapine
and the CLZ-to-N-desmethylclozapine metabolic ratio,
independent of smoking habits9,24. When adjusting for
known smoking habits, which have a major effect on CLZ
metabolism13,14, we identified a novel locus in the NFIB
gene (rs28379954 T>C) associated with a significant
reduction in CLZ serum concentrations.
According to our findings in the GWAS analysis
adjusting for smoking habits, heterozygous carriers of the
minor rs28379954 C allele are associated with a sub-
stantial decrease in CLZ serum concentration, i.e., an
estimated reduction of 37.6% in the dose-adjusted serum
concentration of CLZ compared with homozygous
Fig. 2 The impact of NFIB rs28379954 minor C allele carriers on clozapine and N-desmethylclozapine concentration, as well as clozapine-
to-N-desmethylclozapine ratio, in relation to smoking habits. a The figure shows all serum concentration measurements (dots) versus clozapine
prescribed daily dose. The regression lines for the various subpopulations are calculated using a linear mixed model analyses without any covariates
(blue, nonsmoking rs28379954 TT carriers; golden, smoking TT carriers; green, nonsmoking CT carriers; red, smoking CT carriers). The figures show the
impact of rs28379954 minor C allele carriers on dose-adjusted serum concentration of clozapine (C/D ratio; b), N-desmethylclozapine (C/D ratio;
c) and clozapine-to-N-desmethylclozapine ratio (d) in relation to smoking habits. The ratios were analyzed by linear mixed model including sex, age,
and sampling time (time between last dose and blood sampling) as covariates. The numbers of patients within each subpopulation are shown in the
various bars.
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carriers of the wild type allele (rs28379954 TT). This effect
was only identified after adjusting for individually ascer-
tained smoking habits, and not when controlling for a
polygenic score proxy measure of smoking, as performed
in the recent GWAS by Pardiñas et al.16. Smokers com-
prised 61.1% of the included patient population, a typical
prevalence for a sample of individuals with schizo-
phrenia36. These results suggest that patients hetero-
zygous for the minor C allele, representing 7.6% of the
current study population, are at risk of subtherapeutic
CLZ serum concentrations at standard recommended
CLZ dosing. Indeed, the patients carrying the minor C
allele had significant lower absolute CLZ serum con-
centration regardless of their smoking habits; however,
smoking was shown to reinforce this effect. Since smokers
are already prone to lower CLZ serum concentrations,
smokers carrying the minor C allele may represent a
subpopulation particularly vulnerable to suboptimal
concentration and treatment failure. This is supported by
the more than threefold higher proportion of CLZ con-
centration measurements below the therapeutic reference
in smoking C carriers vs. nonsmoking TT carriers in our
population. Thus, genotyping of rs28379954 may poten-
tially aid individualized dosing of CLZ in clinical practice
to ensure optimal treatment response.
The rs28379954 T>C polymorphism was not associated
with the pharmacokinetic variability of either the dose-
adjusted serum concentration of N-desmethylclozapine or
the CLZ-to-N-desmethylclozapine metabolic ratio in the
GWAS analyses, suggesting that the mechanisms behind
the reduced CLZ levels may be related to an increased
formation of other CLZ metabolites than N-desmethyl-
clozapine. The SNP rs28379954 is located in an intronic
region of the NFIB gene, which encodes a transcription
factor (NFIB) that is expressed in several tissues, such as
lungs, liver, kidneys, and brain37,38. NFIB plays a role
during embryotic development by initiating tissue differ-
entiation in the fetus38, but has not previously been
reported to regulate the expression or activity of drug-
metabolizing enzymes.
From the findings of the present study, it may be hypo-
thesized that the rs28379954 T>C polymorphism affects the
transcription of genes involved in CLZ metabolism. Based
on observations of a quantitatively higher and statistically
stronger difference in CLZ levels in smoking than non-
smoking CT vs. TT carriers (Fig. 2b), the most relevant
hypothesis is that NFIB modulates the expression of the
ligand-activated transcription factor aryl hydrocarbon
receptor (AhR), which is induced by smoking and impor-
tant for CLZ metabolism. However, experimental studies
are required to elucidate the functional impact of the NFIB
gene on CLZ metabolism. In addition, it should be inves-
tigated if rs28379954 genotype is associated with formation
of metabolites with potential impact on CLZ toxicity.
Recently, Pardiñas et al. showed an association
between the SNP rs2472297 in CYP1A1/1A2 locus and
CLZ serum concentration in a British cohort16, which
was not replicated in the present study. In their study,
however, smoking habits data were not available, and
polygenic risk scores for smoking were therefore used
as a proxy measure of smoking habits instead. Notably,
cigarette smoking has been shown to reduce CLZ levels
by ~30–50% by inducing CYP1A1/1A223–25, and up to
60% of individuals with schizophrenia are smokers36.
Given the large effect of smoking on CLZ metabolism,
and the high prevalence of smoking in people with
schizophrenia, the differences in accounting for smok-
ing habits may explain the discrepancy between the
studies. It should be noted that in the present study, the
SNP rs2472297 in the CYP1A1/1A2 locus had a call rate
of 64.2% and was therefore excluded from GWAS
analyses. However, no other SNPs within the previously
defined CYP1A1/1A2 locus (15:74817689–75404506)
showed association signals, without and after adjusting
for smoking habits, respectively. These results suggest
that caution is required when polygenic risk score is
utilized as a proxy for smoking.
Similarly to Pardiñas et al.16, we found that the genetic
variants in the UGT2B10 locus are associated with the N-
desmethylclozapine serum concentration, and hence the
CLZ-to-N-desmethylclozapine metabolic ratio, irrespective
of smoking habits. In particular, the intergenic minor alleles
of the lead SNPs rs1670747 (4:69601886–70138176) and
rs2926038 (4:69544277–70340670) are responsible for
decreasing N-desmethylclozapine levels and increasing the
CLZ-to-N-desmethylclozapine ratio by ~21% and 25%,
respectively. UGT2B10 is involved in N-glucuronidation of
a variety of psychotropic drugs including CLZ, and likely N-
desmethylclozapine39. These variants might be of potential
relevance to genotype before starting CLZ treatment, since
increasing N-desmethylclozapine level has been associated
with positive effects of CLZ treatment6,40, but further stu-
dies are required to elucidate if UGT2B10 genotype has an
impact on the clinical response of CLZ.
Our results add support to the hypothesis that the
genetic architecture of CLZ metabolism is driven by few
variants with large effect sizes16,18, in line with typical
pharmacogenetics findings19,20. Despite our sample being
approximately sixfold smaller than the British GWAS16,
we robustly replicate their findings that the UGT2B10
locus on chromosome 4 is associated with N-desmethyl-
clozapine serum concentration, and hence the CLZ-to-N-
desmethylclozapine metabolic ratio. These results, in
addition to the 97% overlap in rs28379954 T>C genotypes
by GWAS and targeted Taqman analyses, increase our
confidence that the novel locus we identified to be asso-
ciated with CLZ serum concentration (rs28379954), after
adjusting for smoking habits, is a true positive and not a
Smith et al. Translational Psychiatry          (2020) 10:198 Page 8 of 10
spurious association due to winner’s curse. Additional
studies are still required to replicate this association in
independent cohorts of CLZ-treated schizophrenia
patients with known smoking habits.
The use of TDM data for research purposes is associated
with some methodological limitations, where potential
nonadherence is a relevant issue creating ‘nonbiological’
variability in the concentration phenotype. Unknown co-
medications may also alter CLZ metabolism and con-
centration, but in the current material, co-prescription of
the most relevant interacting drugs was accounted for, i.e.,
phenytoin, phenobarbital, carbamazepine, and fluvoxamine,
which all change the CLZ concentration several-fold41,42. In
addition, information on comorbidity, weight, and potential
consumption of dietary supplements potentially affecting
concentration phenotypes was not available. The amount of
cigarette consumption could not be obtained, but the
enzyme-inducing effect of smoking is little affected by the
degree of cigarette consumption25.
In conclusion, the present GWAS on CLZ pharmaco-
kinetics, adjusting for known smoking habits, identified a
novel variant in the NFIB gene (rs28379954) associated
with a significant reduction in CLZ levels. These results
suggest that patients carrying the minor C allele are at risk
of subtherapeutic CLZ serum concentrations, particularly
in smokers. Thus, genotyping of rs28379954 may
potentially aid individualized dosing of CLZ in clinical
practice.
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